Delivery Order SPE2DB24D1007-SPE2DB25FCDAJ
- Not listed
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, received a delivery order valued at $36,378.29 for Ozempic 2 mg/dose (8 mg/3 mL) 3 mL vials from the Defense Medical Supply Chain on July 28, 2025. The contract is a firm fixed price delivery order with an ultimate completion date of July 29, 2025, and was awarded on a competitive basis without set-aside designation. This delivery order represents a child contract executed under...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency on August 29, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 ml) 3ml vials. The contract is valued at $19,050.96 and carries an ultimate completion date of September 2, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating it was awarded through open competition. The award represents a child contract under...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on August 19, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 ml) 3 ml vials, with a contract ceiling value of $91,339.91. This is a firm fixed-price, non-competitive set-aside delivery order utilizing a competitive award process. The work will be performed at the contractor's facility in Conshohocken, Pennsylvania, with an ultimate completion date of August 20, 2025. This delivery order falls...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on August 20, 2025, by the Defense Logistics Agency for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL quantities, with a contract value of $11,350.99 and an ultimate completion date of August 21, 2025. This is a firm fixed price delivery order with no set-aside designation, awarded through competitive procurement. The award represents a child order under AmerisourceBergen's larger...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) for pharmaceutical supplies on July 18, 2025, with an ultimate completion date of July 21, 2025. The contract is valued at $30,825.02 and covers the delivery of Ozempic 1 mg/dose (4 mg/3 mL) 3 mL vials to support federal medical procurement needs. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was made through open competition. The place of performance...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on August 18, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials. The contract is valued at $3,759.96 and carries a firm fixed price with an ultimate completion date of August 19, 2025. The award utilized competitive procurement procedures with no set-aside designation. The place of performance is identified as the vendor's corporate office in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $3,216.66 on August 5, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 ml) in 3 ml vials. This competitively awarded, firm fixed-price delivery order is set to be completed by August 6, 2025, with performance conducted at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, received a competitive delivery order from the Defense Logistics Agency valued at $5,377.59 for Ozempic 1 mg/dose (4 mg/3 ml) 3 ml vials. The contract is a firm fixed price delivery order awarded on July 21, 2025, with an ultimate completion date of July 22, 2025. This award was not designated as a set-aside contract and represents a small-value transaction typical of the company's...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency on August 8, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials. This firm fixed-price delivery order, valued at $3,138.37, was competitively awarded without set-aside designation and is scheduled for completion by August 11, 2025. The order will be fulfilled from the vendor's location in Conshohocken,...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on August 25, 2025, by the Defense Logistics Agency to supply Ozempic 2 mg/dose (8 mg/3 ml) injectable medication. The contract, valued at $14,490.85, represents a firm fixed price delivery order with an ultimate completion date of August 26, 2025. This award was not designated as a set-aside contract and was competitively awarded through open competition. The...
- SPE2DB24D1007Indefinite Delivery Contract
- SPE2DB24D1007-SPE2DB25FCDAJDelivery Order
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $54,717.86 by the Defense Logistics Agency (DLA) on August 28, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials. The contract is characterized as a firm fixed price delivery order with an ultimate completion date of August 29, 2025, and was competitively awarded with no set-aside designation. This award is a child contract issued under a larger indefinite delivery vehicle, reflecting the company's established relationship with the federal medical supply chain and its capability to meet pharmaceutical procurement requirements through open competition. This delivery order is issued under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. This prime contract vehicle serves as a comprehensive pharmaceutical support mechanism for military healthcare programs worldwide, enabling the supply of brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains. The award demonstrates the company's ongoing role as a critical vendor supporting Defense Health Agency operations and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $54.7k | 8/28/25 |